The clinical sign of children’s kidney and urinary tract petrification diseases and the result of eswl Background: A substance exchange disorder where stones form in the kidney or urinary tract with a tendency toward inheritance is called urinary tract petrification disease. In many countries throughout the world, the incidence of urinary tract petrification disease is one to fifteen percent. Urinary tract permeability disease affects 7% of people under the age of 17. Due to the unique nature of the habitat, the incidence of urinary tract petrification disease is higher in India, Thailand, Scandinavian countries, and the Caucasian, Ural, Siberia, and Equator areas. However, the incidence of urinary tract petrification disease spread is two to three percent for children, but the reoccurance risk is 6.5–54 percent. In our country’s case, J. Horloo’s 1993 research indicates that 4.1 to 4.7 percent of kidney and urinary tract patients have urinary tract disease. During urinary tract disease, the common symptoms are abdominal pain, macro- and microhematuria, and kidney and renal bacterial infection. But in younger children, those symptoms are quite grim. In the last 15 years, mongolian’s urine’s oxalate stone’s volume increased by 5 times and mixed stones decreased by 2.5 times. The research of G. Erdenetsetseg’s 1990–1998 study on 305 children and the 2001–2003 study on 161 children indicate that the incidence of urinary tract disease is high between ages 1-3, and 65 percent of the stones consist of calcium oxalate. In 1980, German scientists invented the stone crushing technology using electrohydraulic shockwaves, which turned out to be a beneficial treatment for kidney surgery practice. The National Hospital for Maternal and Child Health's kidney surgery team had 17 surgeries in 2015, 19 surgeries in 2016, 24 surgeries in 2017, and 28 surgeries in 2018, and all of those surgeries were done and treated open. In the last 10 years of our country, children’s urinary tract petrification disease has gradually increased, but research on those diseases risks and factors is lacking. Also, the stone crushing method is necessary for our country’s children's treatment. That’s why we decided to do research on the risk factors of urinary tract disease and its relation to the stone crushing method. Aim: Describe the features of children’s kidney and urinary tract petrification disease and study the stone crushing method’s results. Materials and methods: The study was done between December of 2019 and April of 2022, with the assistance of NCMCH's children's kidney surgery team. Within the parameter of the first objective, within the group of cases of kidney and urinary tract disease, there were 13 children under the age of 17. The research study was conducted cross sectional. The research results were processed by the SPSS 25 program. On the seventh meeting of the health ministry, we got the acceptance of a research patent with the assistance of EHEMUT. Results: The research group consisted of 13 children ages 0–17. The average age of participants was 10.6+-4.2.74. 4 percent of it consisted of men. The research of symptoms showed that back pain n = 13 (100), right side abdominal pain n = 13 (100), disurie n = 3 (23.1), mouth drying n = 2 (15.4), nausea n = 3 (23.1), urine with blood n = 10 (76.9), urine with smell n = 9 (69.2). The position of the stone consisted of 8 (61.5) in the kidney cup, 8 in the kidney cradle. Showing it in which kidney showed that 8 (61.5) were in the right kidney, 3 (23.1) in the left kidney, and 2 (15.4) in both kidneys. The density of the stones was n = 265.8+ 41.9 on average. Kidney stone coming out time was measured by Caplan-Myer’s survivability scale. The stones on the right side of the kidney came out within 14 days on average, while the left and both-sided kidney stones came out within 30 days. Conclusions: 1. Showing the number of stones and locations indicates that 8 (61.5) were in the right kidney, 3 (23.1) in the left kidney, and 2 (15.4) in both kidneys. 2. The results of Caplan-Meyer's scale indicate that kidney stones within the right kidney came out within 14 days, and left- or both-sided stones came out within 30 days.

Background: There are 13283 people per 100 000 were diagnosed with skin cancer in 2016. Skin cancer is reported not widely in Mongolia. However, melanoma and non-melanoma new case are gradually increasing since 2010. Rhubarb is an old and well-known traditional Mongolian herbal medicine. Rhubarb is rich of bioactive compounds and widely distributed around Mongolia. People are still using Rhubarb as in food consumption and traditional medical treatments. Yet, there is not reported any therapeutic effect of rhubarb based on scientific research.PurposeTo investigate the anti-cancer activities of rhubarb (Rheum undulatum.L), a new herbal preparation from Mongolia, on B16F10 cells Material and Methods: The shoot of rhubarb was soaked with 40% ethanol and methanol. Murine melanoma B16F10 and RAW264.7 macrophage cell lines were purchased from the American Type Culture Collection (ATCC). Cell viability was determined CCK-8 assay. The antimigratory effect of Rhubarb (50-400 μg/μl) was investigated by a wound healing assay for 12 hours. Apoptosis was then evaluated by Western blot analysis. All experiments conducted at Core laboratory of Mongolian national university of medical sciences and Genomics laboratory of Mongolian university of life sciences from November 2015 to February 2017. Results: Ethanol and methanol extract of rhubarb inhibited the proliferation of B16F10 and RAW264.7 cells. In WHMA, cell migration was gradually decreased by concentrate dependent groups compare to the control group. Furthermore, protein expression PARP, Akt, BCL2, BAX and mTOR was investigated. BAX, Akt were down-regulated by rhubarb extraction as expected. DNA fragmentation assay have shown a dose dependent increase in the fragmentation of the DNA signifying apoptotic changes in the R.u extract treated B16F10 cells. Conclusion Rhubarb (Rheum undulatum.L) shows promising anti-cancer activity and can be useful in therapeutic treatment of skin cancer.